Vaxart, Inc. (NASDAQ:VXRT - Get Free Report)'s share price passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $0.74 and traded as low as $0.46. Vaxart shares last traded at $0.47, with a volume of 2,133,998 shares trading hands.
Vaxart Trading Down 0.4 %
The company has a fifty day moving average of $0.70 and a 200-day moving average of $0.74. The company has a market capitalization of $106.92 million, a price-to-earnings ratio of -1.15 and a beta of 1.69.
Institutional Trading of Vaxart
Several large investors have recently bought and sold shares of VXRT. Geode Capital Management LLC boosted its holdings in shares of Vaxart by 2.3% during the 4th quarter. Geode Capital Management LLC now owns 2,601,139 shares of the biotechnology company's stock worth $1,723,000 after purchasing an additional 57,911 shares during the last quarter. Silverarc Capital Management LLC boosted its stake in Vaxart by 7.8% during the fourth quarter. Silverarc Capital Management LLC now owns 1,077,782 shares of the biotechnology company's stock worth $714,000 after buying an additional 77,782 shares during the last quarter. Squarepoint Ops LLC grew its holdings in Vaxart by 95.0% in the 4th quarter. Squarepoint Ops LLC now owns 516,798 shares of the biotechnology company's stock valued at $342,000 after buying an additional 251,789 shares in the last quarter. Raymond James Financial Inc. purchased a new position in shares of Vaxart during the 4th quarter worth $129,000. Finally, Bank of America Corp DE grew its holdings in shares of Vaxart by 10.8% in the fourth quarter. Bank of America Corp DE now owns 184,447 shares of the biotechnology company's stock valued at $122,000 after purchasing an additional 17,942 shares during the period. Hedge funds and other institutional investors own 18.05% of the company's stock.
About Vaxart
(
Get Free Report)
Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.
Further Reading
Before you consider Vaxart, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vaxart wasn't on the list.
While Vaxart currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
